Enliven Therapeutics, Inc.

ELVN • Biotechnology

$59.32

▼ -0.33 (-0.55%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$3.93B

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez saludable · 28.66Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:48 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$59.32

Change-0.55%

Shares Out66.17M

Market Cap$3.93B

Enterprise Value$3.03B

52W Range14.79 - 62.32

Beta0.24

P/E-37.06

P/B4.39

P/FCF-58.55

EV/EBITDA-26.44

EV/FCF-45.21

Price$59.32

Change-0.55%

Shares Out66.17M

Market Cap$3.93B

Enterprise Value$3.03B

52W Range14.79 - 62.32

Beta0.24

P/E-37.06

P/B4.39

P/FCF-58.55

EV/EBITDA-26.44

EV/FCF-45.21

Earnings Yield-2.70%

FCF Yield-1.71%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio28.66

Quick Ratio28.66

Target$76.00

Target Upside28.12%

Target Median$78.00

Target Range65.00 - 82.00

Volume489.94K

Avg Volume1.28M

EPS Surprise0.06

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

88/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez saludable · 28.66Rentabilidad débil

Analyst view

Analyst sentiment and price target

ELVN

Analyst sentiment

Based on 9 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$62.00

Promedio

$73.40

Mediana

$78.00

Alto

$82.00

Resumen de la compañía

IPO: 3/12/2020

Industria: Biotechnology

P/B i: 4.39

Deuda / Patrimonio i: 0.00

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 28.66

Ratio rápido: 28.66

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 1 venta interna de alto volumen detectada

Derynck Mika K

Transacción: 08/04/2026

VENTA

Cambio

-23,364

Precio

$14.85

Presentación

08/06/2026

Tipo

VENTA

Derynck Mika K

Transacción: 08/04/2026

VENTA

Cambio

-158,795

Precio

$60.21

Presentación

08/06/2026

Tipo

VENTA

Collins Helen Louise

Transacción: 07/17/2026

VENTA

Cambio

-63

Precio

$53.92

Presentación

07/21/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Derynck Mika K	VENTA	-23,364	$14.85	08/04/2026	08/06/2026
Derynck Mika K	VENTA	-158,795	$60.21	08/04/2026	08/06/2026
Collins Helen Louise	VENTA	-63	$53.92	07/17/2026	07/21/2026
Collins Helen Louise	VENTA	-5,000	$2.48	07/17/2026	07/21/2026
Hohl Benjamin	VENTA	-123	$53.87	07/17/2026	07/21/2026
Hohl Benjamin	VENTA	-1,072	$2.48	07/17/2026	07/21/2026
Kunkel Lori Anne	VENTA	-5,889	$50.84	07/06/2026	07/08/2026
ORBIMED ADVISORS LLC	VENTA	-1,477	$45.00	06/22/2026	06/24/2026
Collins Helen Louise	VENTA	-1,133	$44.74	06/17/2026	06/22/2026
Collins Helen Louise	VENTA	-5,000	$2.48	06/17/2026	06/22/2026
Hohl Benjamin	VENTA	-1,238	$44.75	06/17/2026	06/22/2026
Hohl Benjamin	VENTA	-6,018	$2.48	06/17/2026	06/22/2026
ORBIMED ADVISORS LLC	VENTA	-9,086	$45.02	06/15/2026	06/17/2026
Kunkel Lori Anne	VENTA	-354	$35.82	06/05/2026	06/09/2026
Collins Helen Louise	VENTA	-223	$41.21	05/18/2026	05/20/2026
Collins Helen Louise	VENTA	-5,000	$2.48	05/18/2026	05/20/2026
Collins Helen Louise	VENTA	-2,441	$48.06	04/17/2026	04/21/2026
Collins Helen Louise	VENTA	-5,000	$2.48	04/17/2026	04/21/2026
Collins Helen Louise	VENTA	-40,000	$35.10	03/25/2026	03/27/2026
Collins Helen Louise	VENTA	-40,000	$2.48	03/25/2026	03/27/2026

Sobre la compañía

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Fuente - Link

Competidores

ATAI DNTH IMTX INBX NKTR ORIC PGEN RLAY SANA SNDX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Enliven Therapeutics to Present at Upcoming Investor Conferences

BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, Sept.

PRNewsWire

Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-competitive inhibitor, aiming for a differentiated, chronic-use profile in a sequential treatment paradigm. Phase 1 data show 61% MMR at 80 mg daily, with favorable safety and convenience for chronic administration, supporting potential in earlier-line CML settings.

Seeking Alpha

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting, taking place September 9-12, 2026, at the George R.

PRNewsWire

BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN

BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,359,704 shares of the company's stock, valued at approximately $221,255,000. BlackRock Inc. owned 7.16% of Enliven Therapeutics at

Defense World

Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).

Benzinga

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	-0.44	-0.38	0.06
2026-03-03	-0.42	-0.48	-0.06
2025-11-12	-0.43	-0.32	0.11
2025-08-13	-0.53	-0.49	0.04
2025-05-14	-0.51	-0.57	-0.06
2025-03-13	-0.53	-0.46	0.07
2024-11-13	-0.52	-0.48	0.04
2024-08-13	-0.58	-0.41	0.17
2024-05-14	-0.58	-0.54	0.04
2024-03-14	-0.56	-0.47	0.09
2023-11-09	-0.49	-0.51	-0.02
2023-08-10	-0.4	-0.41	-0.01